Monogenic diseases that can be cured by liver transplantation

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 67, Issue 3, Pages (September 2017)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Volume 66, Issue 3, Pages (March 2017)
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
The management of childhood liver diseases in adulthood
Volume 53, Issue 5, Pages (November 2010)
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
The evidence supports a viral aetiology for primary biliary cirrhosis
Living donor liver transplantation: is the hype over?
K. L. Nash, M. E. Allison, D. McKeon, D. J. Lomas, C. S. Haworth, D
European Association for the Study of the Liver  Journal of Hepatology 
Reply to: “DCD consensus and futility in liver transplantation”
Volume 44, Pages S19-S24 (January 2006)
The place of downstaging for hepatocellular carcinoma
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Familial amyloid polyneuropathy and liver transplantation
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Cirrhosis and other liver disease in cystic fibrosis
Volume 58, Issue 3, Pages (March 2013)
Volume 62, Issue 3, Pages (March 2015)
Volume 59, Issue 3, Pages (September 2013)
Volume 53, Issue 5, Pages (November 2010)
Volume 44, Issue 4, Pages (April 2006)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Giovanni Addolorato, Antonio Mirijello, Pablo Barrio, Antoni Gual 
A.H. Gifford  Journal of Cystic Fibrosis 
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Paul C. Adams, James C. Barton  Journal of Hepatology 
Immigration and viral hepatitis
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 64, Issue 6, Pages (June 2016)
Disease disclosure in individuals with cystic fibrosis: Association with psychosocial and health outcomes  Adrienne P. Borschuk, Robin S. Everhart, Michelle.
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Shunt dysfunction: Is it suitable as the primary end point in transjugular intrahepatic portosystemic shunt trials?  Jingzhi Cai, Wengang Guo, Chuangye.
Liver transplantation in children
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Comment on the article “Age and liver transplantation”
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Outcomes in liver transplantation: Does sex matter?
Presentation transcript:

Monogenic diseases that can be cured by liver transplantation Stefano Fagiuoli, Erica Daina, Lorenzo D’Antiga, Michele Colledan, Giuseppe Remuzzi  Journal of Hepatology  Volume 59, Issue 3, Pages 595-612 (September 2013) DOI: 10.1016/j.jhep.2013.04.004 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 ELTR and Bergamo experiences in adult and paediatric in LT for monogenic diseases: ELTR (1968–2010) and Bergamo (1998–2012). α1ATD, alpha1 anti-trypsin deficiency; CF, cystic fibrosis; CN1, Crigler Najjar type 1; FAP, familial amyloid polyneuropathy; GSD, glycogen storage disease; HH, hereditary haemochromatosis; HUS, haemolytic uraemic syndrome; OA, organic acidurias; PH, primary hyperoxalurias; PFIC, progressive familial intrahepatic cholestasis; UCD, urea cycle disorders; WD, Wilson’s disease. Journal of Hepatology 2013 59, 595-612DOI: (10.1016/j.jhep.2013.04.004) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2013 59, 595-612DOI: (10. 1016/j. jhep. 2013. 04 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions